Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a rapid-progressing hematologic malignancy characterized by the uncontrolled proliferation of immature myeloid cells. Current cancer research focuses on understanding the genetic and molecular basis of AML to develop targeted therapies. Advances in genomics have identified mutations in genes such as FLT3, NPM1, and DNMT3A, providing insights into disease pathogenesis and potential therapeutic targets. Novel treatments, including FLT3 inhibitors and immune-based therapies like monoclonal antibodies and CAR-T cells, are under investigation. Additionally, researchers are exploring the role of the bone marrow microenvironment in AML progression and resistance to therapy, aiming to improve patient outcomes through personalized medicine.